Cytokinetics CYTK CH — Operating Lease Right Of Use Asset

Similar metrics at other companies

CHRWOther locations — Right-of-use lease assets

$66.4M-29.7%

MTDChinese Operations Segment — Operating Lease, Right-of-Use Asset

$2.9M-3.3%

EXELOperating Lease, Right-Of-Use Asset And Other Non-Current Assets

$282.87M+26.5%

FBR

FBRTChicago, Illinois — Operating right of use asset, net of amortization

$5.75M—

TPX

TPXAll other — Operating Lease ROU Assets

——

UHAL.BProperty And Casualty Insurance — Operating Lease Right Of Use Asset

——

Questions, answered.

What is Cytokinetics's CH — operating lease right of use asset?

Cytokinetics (CYTK) reported CH — operating lease right of use asset of $2.6M in Q4 2025.

What does CH — operating lease right of use asset mean?

The balance sheet value of the right to use leased property and equipment assigned to the CH segment.

How do you interpret CH — operating lease right of use asset?

An increase indicates expansion of the physical footprint or new lease agreements within the segment, while a decrease suggests lease expirations or asset impairments.

How does CH — operating lease right of use asset compare across companies?

Peers in the biotechnology sector typically report similar ROU assets based on their real estate footprint for R&D and administrative operations.